Paper39200055
Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.
Chihara S and 5 others. Antibiotics (Basel), 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI. Papers, record 39200055. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39200055
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12660337 | Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. | J Am Soc Nephrol | 2003 | https://conductscience.org/library/papers/12660337 | PubMed |
| 2 | 29091190 | Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/29091190 | PubMed |
| 3 | 16211527 | Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. | Int J Artif Organs | 2005 | https://conductscience.org/library/papers/16211527 | PubMed |
| 4 | 36005753 | Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/36005753 | PubMed |
| 5 | 21914174 | Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. | Crit Care | 2011 | https://conductscience.org/library/papers/21914174 | PubMed |
| 6 | 12940901 | Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. | Artif Organs | 2003 | https://conductscience.org/library/papers/12940901 | PubMed |
| 7 | 20479205 | Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20479205 | PubMed |
| 8 | 24026297 | De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. | Intensive Care Med | 2014 | https://conductscience.org/library/papers/24026297 | PubMed |
| 9 | 38627763 | Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis. | Crit Care | 2024 | https://conductscience.org/library/papers/38627763 | PubMed |
| 10 | 24886826 | β-lactam antibiotic concentrations during continuous renal replacement therapy. | Crit Care | 2014 | https://conductscience.org/library/papers/24886826 | PubMed |
| 11 | 25636084 | The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. | Crit Care | 2014 | https://conductscience.org/library/papers/25636084 | PubMed |
| 12 | 29102324 | Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. | Lancet Infect Dis | 2018 | https://conductscience.org/library/papers/29102324 | PubMed |
| 13 | 26903338 | The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). | JAMA | 2016 | https://conductscience.org/library/papers/26903338 | PubMed |
| 14 | 34999376 | Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1). | J Crit Care | 2022 | https://conductscience.org/library/papers/34999376 | PubMed |
| 15 | 37125925 | Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/37125925 | PubMed |
| 16 | 30304491 | Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. | J Antimicrob Chemother | 2018 | https://conductscience.org/library/papers/30304491 | PubMed |
| 17 | 21884474 | In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. | Ther Apher Dial | 2011 | https://conductscience.org/library/papers/21884474 | PubMed |
| 18 | 18027987 | Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. | Clin Pharmacokinet | 2007 | https://conductscience.org/library/papers/18027987 | PubMed |
| 19 | 12970037 | Vital organ blood flow during hyperdynamic sepsis. | Chest | 2003 | https://conductscience.org/library/papers/12970037 | PubMed |
| 20 | 32301057 | Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial. | Pharmacol Rep | 2020 | https://conductscience.org/library/papers/32301057 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42711757 | Prediction of the clinical outcomes of imipenem and meropenem in patients with treatment-associated AKI and death via machine learning models combined with pharmacokinetic parameters: A retrospective cohort study. | Sci Prog | 2026 | https://conductscience.org/library/papers/42711757 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39200055
GET https://conductscience.org/api/papers/v1/39200055/references?page=2